Risk stratification for inhibitor development at first treatment for severe hemophilia A: A tool for clinical practice

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 12, 2008, Pages 2048-2054

  ter Avest, P C ^a   Fischer, K ^a,b   Mancuso, M E ^c   Santagostino, E ^c   Yuste, V J ^d   van den Berg, H M ^b   van der Bom, Johanna G ^a,e  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antibody; Hemophilia A; Intensive treatment; Risk score

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; KOGENATE BAYER; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ARTICLE; BLEEDING; CHILD; DISEASE SEVERITY; FAMILY HISTORY; GENE MUTATION; GENETIC RISK; HEMOPHILIA A; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT;

ALGORITHMS; ANTIBODIES; ANTIBODY FORMATION; FACTOR VIII; HEMOPHILIA A; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE;

EID: 56749175272     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03187.x     Document Type: Article

References (41)

1. Astermark J, Morado M, Rocino A, van den Berg HM, Von DM, Gringeri A, Mantovani L, Garrido RP, Schiavoni M, Villar A, Windyga J. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 2006; 12: 363-71.
2. Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: The CANAL cohort study. Blood 2007; 109: 4648-54.
3. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: A systematic review. Haemophilia 2003; 9: 418-35.
4. Astermark J, Oldenburg J, Escobar M, White GC, Berntorp E. The Malmo International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica 2005; 90: 924-31.
5. Goudemand J, Rothschild C, Demiguel V, Vinciguerrat C, Lambert T, Chambost H, Borel-Derlon A, Claeyssens S, Laurian Y, Calvez T. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46-51.
6. Astermark J, Berntorp E, White GC, Kroner BL. The Malmo International Brother Study (MIBS): Further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001; 7: 267-72.
7. Astermark J. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia. Haemophilia 2006; 12 (Suppl. 3): 52-60.
8. Schwaab R, Brackmann HH, Meyer C, Seehafer J, Kirchgesser M, Haack A, Olek K, Tuddenham EG, Oldenburg J. Haemophilia A: Mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-6.
9. Oldenburg J, Schroder J, Brackmann HH, Muller-Reible C, Schwaab R, Tuddenham E. Environmental and genetic factors influencing inhibitor development. Semin Hematol 2004; 41: 82-8.
10. Aledort LM, Dimichele DM. Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia 1998; 4: 68.
11. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999; 5: 145-54.
12. Astermark J, Oldenburg J, Carlson J, Pavlova A, Kavakli K, Berntorp E, Lefvert AK. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108: 3739-45.
13. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107: 3167-72.
14. Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007; 5: 263-5.
15. Chalmers EA, Brown SA, Keeling D, Liesner R, Richards M, Stirling D, Thomas A, Vidler V, Williams MD, Young D. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007; 13: 149-55.
16. van der Bom JG, Mauser-Bunschoten EP, Fischer K, van den Berg HM. Age at first treatment and immune tolerance to factor VIII in severe hemophilia. Thromb Haemost 2003; 89: 475-9.
17. Lorenzo JI, Lopez A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: The importance of patient age. Br J Haematol 2001; 113: 600-3.
18. Gouw SC, van den Berg HM, Le CS, van der Bom JG. Treatment characteristics and the risk of inhibitor development: A multi-center cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost 2007; 5: 1383-90.
19. Sharathkumar A, Lillicrap D, Blanchette VS, Kern M, Leggo J, Stain AM, Brooker L, Carcao MD. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 2003; 1: 1228-36.
20. Morado M, Villar A, Jimenez YV, Quintana M, Hernandez NF. Prophylactic treatment effects on inhibitor risk: Experience in one centre. Haemophilia 2005; 11: 79-83.
21. Santagostino E, Mancuso ME, Rocino A, Mancuso G, Mazzucconi MG, Tagliaferri A, Messina M, Mannucci PM. Environmental risk factors for inhibitor development in children with haemophilia A: A case-control study. Br J Haematol 2005; 130: 422-7.
22. Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic information. Ann Intern Med 1999; 130: 515-24.
23. Reilly BM, Evans AT. Translating clinical research into clinical practice: Impact of using prediction rules to make decisions. Ann Intern Med 2006; 144: 201-9.
24. Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White G III, Lee M. A multicenter study of recombinant factor VIII (Recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994; 83: 2428-35.
25. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients. Semin Hematol 2001; 38: 52-9.
26. Giangrande PL. Safety and efficacy of KOGENATE(R) Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs). Haemophilia 2002; 8 (Suppl. 2): 19-22.
27. Gruppo R, Bray GL, Schroth P, Perry M, Gomperts ED. Safety and immunogenicity of recombinant factor VIII (Recombinate) in previously untreated patients (PUPs): A 6.5 year update. The Recombinate PUP study Group. Thromb Haemost 1997; 77: 162 (abstract PD-663).
28. Kreuz W, Gill JC, Rothschild C, Manco-Johnson MJ, Lusher JM, Kellermann E, Gorina E, Larson PJ. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: Results of an international clinical investigation. Thromb Haemost 2005; 93: 457-67.
29. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993; 328: 453-9.
30. Lusher JM, Lee CA, Kessler CM, Bedrosian CL. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003; 9: 38-49.
31. Lusher JM, Roth DA. The safety and efficacy of B-domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: An update. Haemophilia 2005; 11: 292-3.
32. Schroder J, El-Maarri O, Schwaab R, Muller CR, Oldenburg J. Factor VIII intron-1 inversion: Frequency and inhibitor prevalence. J Thromb Haemost 2006; 4: 1141-3.
33. van der Heijden GJ, Donders AR, Stijnen T, Moons KG. Imputation of missing values is superior to complete case analysis and the missing-indicator method in multivariable diagnostic research: A clinical example. J Clin Epidemiol 2006; 59: 1102-9.
34. Donders AR, van der Heijden GJ, Stijnen T, Moons KG. Review: A gentle introduction to imputation of missing values. J Clin Epidemiol 2006; 59: 1087-91.
35. van Houwelingen JC, Le Cessie S. Predictive value of statistical models. Stat Med 1990; 9: 1303-25.
36. Matzinger P. The danger model: A renewed sense of self. Science 2002; 296: 301-5.
37. Reipert BM, van Helden PM, Schwarz HP, Hausl C. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors. Br J Haematol 2007; 136: 12-25.
38. Fischer K, van der Bom JG, Mauser-Bunschoten EP, Roosendaal G, Prejs R, de KP, Grobbee DE, van den BM. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002; 99: 2337-41.
39. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
40. Petrini P, Lindvall N, Egberg N, Blomback M. Prophylaxis with factor concentrates in preventing hemophilic arthropathy. Am J Pediatr Hematol Oncol 1991; 13: 280-7.
41. Peerlinck K, Hermans C. Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy. Haemophilia 2006; 12: 579-90.